

A NOVEL BORON CONTAINING GADOLINIUM TEXAPHYRIN

Achintya K. Bandyopadhyaya,¹ Lamine A. Diop,² and Werner Tjarks¹

¹*Division of Medicinal Chemistry & Pharmacognosy, College of Pharmacy, The Ohio State University, Columbus, OH 43210*

²*Collège Universitaire de Saint-Boniface, Winnipeg, MB R2H 0H7, Canada*

Texaphyrins have been discussed as potential cancer therapeutic agents. Motexafin, a gadolinium metal containing texaphyrin is currently in clinical studies as a cancer chemotherapeutic agent, as a MRI agent, and as a X-radiation sensitizer. Gadolinium texaphyrins substituted with boron clusters could lead to novel cancer therapeutic and diagnostic agents in particular for use in combined gadolinium and boron neutron capture therapy (Gd/B NCT). Synthetic progresses towards novel boron and gadolinium containing texaphyrins, their characterization by MS and UV-Vis spectroscopy, and the results of their preliminary biological evaluation will be discussed.